Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 4, 2010, Pages 210-217

  Uckun, Fatih M ^a,b,c   Dibirdik, Ilker ^a   Qazi, Sanjive ^a,d   Yiv, Seang ^a  

^a PARKER HUGHES INSTITUTE   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d GUSTAVUS ADOLPHUS COLLEGE   (United States)

Author keywords

Acute lymphoblastic leukemia cells; Anti leukemia agent; CAS 202475 60 3; JAK3 tyrosine kinase inhibitor; WHI P131, nanoparticle constructs

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; JANUS KINASE 3; NANOPARTICLE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIFE TABLE METHOD; MOUSE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PRE B LYMPHOCYTE; XENOGRAFT;

EID: 77951715318     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296275     Document Type: Article

References (40)

1. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds K, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001;20:7925-7934 (Pubitemid 34002969)
2. Jeong EG, Jeong EG, Kim MS, Nam HK, Min CK, Lee S, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008; 14:3716-3721.
3. EumSY, Lee YW, Hennig B, Toborek M. Interplay between epidermal growth factor receptor and Janus kinase 3 regulates polychlorinated biphenyl-induced matrix metalloproteinase-3 expression and transendothelial migration of tumor cells. Mol Cancer Res. 2006;4:361-370 (Pubitemid 44035155)
4. Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Cho S, et al. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT3 pathway in a SKBR3 breast cancer cell line. Cell Signal. 2009;21:892-898.
5. Cance WG, Liu ET. Protein kinases in human breast cancer. Breast Cancer Res Treat. 1995;35:105-114.
6. Uckun FM, Vassilev A, Dibirdik I, Tibbles H. Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally designed inhibitors. Anticancer Agents Med Chem. 2007;7:612-623 (Pubitemid 350237766)
7. Serewko MM, Popa C, Dahler AL, Smith L, Strutton GM, Coman W, et al. Alterations in gene expression and activity during squamous cell carcinoma development. Cancer Res. 2002;62:3759-3765 (Pubitemid 34728858)
8. Sudbeck EA, Liu X, Narla RK, Mahajan S, Ghosh S, Mao C, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999;5:1569-1582 (Pubitemid 29282966)
9. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines. Inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005;167:969-980.
10. Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene. 2003;22:5399-5407 (Pubitemid 37072194)
11. Hu W, Zhang C, Zhang P, Wei D, Zhao Z, Cai M. Inhibition of constitutively activated JAK3 and induction of apoptosis in NALM-6 cell line. Hua Xi Yi Ke Da Xue Bao. 2002;33:25-27.
12. Chen WS, Kung HJ, Yang WK, Lin W. Comparative tyrosine-kinase profiles in colorectal cancers: enhanced arg expression in carcinoma as compared with adenoma and normal mucosa. Int J Cancer. 1999;83;579-584 (Pubitemid 29508032)
13. Martinez-Lostao L, Briones J, Forne I, Martinez-Gallo M, Ferrer B, Sierra J, et al. Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2005;46;435-442 (Pubitemid 40220402)
14. Mori D, Nakafusa Y, Miyazaki K, Tokunaga O. Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays. Pathol Res Pract. 2005;201;777-789 (Pubitemid 43071565)
15. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 2006;10;65-75.
16. Witthuhn BA, Williams MD, Kerawalla H, Uckun, FM. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. Leuk Lymphoma. 1999;32;289-297 (Pubitemid 29087810)
17. Spano JP, Milano G, Rixe C, Fagard R. JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer. 2006;42;2668-2670 (Pubitemid 44584670)
18. Uckun FM, Tibbles H, Ozer Z, Qazi S, Vassilev A. Anti-inflammatory activity profile of JANEX-1 in preclinical animal models. Bioorg Med Chem. 2008;16:1287-1298 (Pubitemid 351191774)
19. Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP, et al. IL-7 dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood. 2004;103:1891-1900.
20. Qazi S, Uckun FM. Gene expression profiles of infant acute lymphoblastic leukemia and its prognostically distinct subsets. Br J Hematol. Forthcoming 2010.
21. Uckun FM, Erbeck D, Qazi S, Venkatachalam TK, Tibbles HE, Vassilev A. Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli (min) mouse model of familial adenomatous polyposis. Arzneimittelforschung. 2007;57(6):320-329 (Pubitemid 47056000)
22. Uckun FM, Dibirdik I, Qazi S. Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase. Arzneimittelforschung. Forthcoming 2010.
23. Uckun FM, Ek O, Liu XP, Chen CL. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4¢ hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. Clin Cancer Res. 1999;5:2954-2962.
24. Uckun FM, Roers BA, Waurzyniak B, Liu XP, Cetkovic-Cvrlje M. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood. 2002;99:4192-4199 (Pubitemid 35332065)
25. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771-782.
26. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316 (Pubitemid 351413909)
27. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5(8):1909-1917 (Pubitemid 44336561)
28. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93-102. (Pubitemid 41773257)
29. Li WM, Mayer L, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharm Exp Ther. 2002;300: 976-983 (Pubitemid 34165004)
30. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88:11460-11464 (Pubitemid 21916061)
31. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta. 1990;1025:143-151.
32. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids. 1990;53:37-46.
33. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1):25-44.
34. Szoka FC, Olson F, Heath T, Vail W, Mayhew E, Papahadjopoulos D. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta. 1990;601(3): 559-571.
35. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta. 1993;1152:253-258.
36. Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ, Cullis PR. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta. 1993;1149:329-338.
37. Uckun FM, Morar S, Qazi S. Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemias. Br J Haematol. 2006;135(4):500-508 (Pubitemid 44583414)
38. Uckun FM, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C. Polo-like kinase 1 (PLK1) as a molecular target to overcome Sykmediated resistance of B-lineage acute lymphoblastic leukemia cells to oxidative stress. Br J Hematol. 2010;148:714-725 Epub 2009 Nov 12.
39. Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, et al, Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia. 1993;7(2):290-297 (Pubitemid 23079242)
40. Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M, et al. BLNK suppresses pre-B cell leukemogenesis through inhibition of JAK3. Blood. 2009;113:1483-1492.